<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423838</url>
  </required_header>
  <id_info>
    <org_study_id>Solifenacin vs Oxybutynin</org_study_id>
    <nct_id>NCT01423838</nct_id>
  </id_info>
  <brief_title>Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder</brief_title>
  <official_title>Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adana Numune Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Akdeniz University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Gaziantep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gaziosmanpasa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kahramanmaras Sutcu Imam University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Adana Numune Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Null hypothesis of the trial is that there is no difference between solifenacin and
      oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life
      measures in patients with overactive bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this two-month follow-up study, the patients with overactive bladder will be randomly
      assigned into two groups (solifenacin or oxybutynin in their usual doses) and will be
      assessed with respect to baseline characteristics and complaints before treatment. After
      initiation of the treatment at first and second months follow-up visits the patients will be
      reassessed with respect to compliance, satisfaction, degree of improvement, reasons for
      dropouts, number and severity of side effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of improvement in overactive bladder symptoms</measure>
    <time_frame>2 months</time_frame>
    <description>The main symptoms of overactive bladder are frequency, urgency, urge incontinence and nocturia (if any). The primary outcome of the trial will be comparison of the improvement of these symptoms in terms of number and severity between two study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of side effects between two study groups</measure>
    <time_frame>2 months</time_frame>
    <description>Outcome measures will be compliance to the study drugs, patient satisfaction, willingness to continue treatment, degree of side effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anticholinergic molecule used in the treatment of overactive bladder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anticholinergic molecule used in the treatment of overactive bladder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>5 mg, oral, once in a day</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>Kinzy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>5 mg, oral, three times in a day</description>
    <arm_group_label>Oxybutynin</arm_group_label>
    <other_name>Uropan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Women between 18-70 years of age, diagnosed to have overactive bladder
        (presence of at least two of the following three main criteria: urgency, urge incontinence,
        frequency and nocturia)

        Exclusion Criteria: Presence of stress urinary incontinence, patients who are still using a
        drug for overactive bladder, pregnant women, women in postpartum period (women on
        lactation), patients who have closed angle glaucoma, patients with chronic constipation,
        having allergy to the ingredients of the drugs, patients having the contraindicated
        conditions listed in the printed instructions of the drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Api, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turkish Republic Ministry of Health Adana Numune Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Murat Api, M.D., PhD.</last_name>
    <phone>+905424241807</phone>
    <email>muratapi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turkish Republic Ministry of Health Adana Numune Training and Research Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01150</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Murat Api, M.D., Ph.D.</last_name>
      <phone>+905424241807</phone>
      <email>muratapi@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hakan Aytan, M.D.</last_name>
      <phone>+905056833866</phone>
      <email>drhakanaytan@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Adana Numune Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Murat Api</investigator_full_name>
    <investigator_title>Associate Professor, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Overactive bladder</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Oxybutynin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

